Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.35 |
| ▸ | MGMT | P16455 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26349201 | 0.81 | KDM4E (0.49) | ALDH1A1KDM4EMEN1HTTKMT2A | |
| SCHEMBL29199650 | 0.78 | HPGD (0.49) | ALDH1A1KMT2AMAPK1TDP1HPGD | |
| SCHEMBL26349189 | 0.78 | MGMT (0.42) | ALDH1A1KDM4EMEN1HTTKMT2A | |
| SCHEMBL26349215 | 0.77 | ALDH1A1 (0.38) | ALDH1A1KDM4EPOLBHPGDNPSR1 | |
| SCHEMBL26349218 | 0.77 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ATDP1POLB | |
| SCHEMBL14499669 | 0.77 | HPGD (0.50) | ALDH1A1KMT2AMAPK1TDP1HPGD | |
| SCHEMBL26349212 | 0.75 | MGMT (0.34) | ALDH1A1KDM4EMEN1HTTKMT2A | |
| SCHEMBL25486877 | 0.73 | ALDH1A1 (0.55) | ALDH1A1KDM4EMEN1HTTKMT2A | |
| SCHEMBL18212282 | 0.70 | MGMT (0.40) | HPGDNPSR1ABCG2MGMT | |
| SCHEMBL25486886 | 0.69 | ALDH1A1 (0.50) | ALDH1A1KDM4EMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | CYP3A43, CYP2C9, CYP2C19 | ALDH1A1 296/4885KDM4E 4396/4885MEN1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.